Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …

Importance It remains unclear whether dabigatran etexilate mesylate is associated with
higher risk of bleeding than warfarin sodium in real-world clinical practice. Objective To …

Objectives To determine the real world safety of dabigatran or rivaroxaban compared with
warfarin in terms of gastrointestinal bleeding. Design Retrospective cohort study. Setting …

Stroke Risk Scores as Predictors of Severe Outcomes in Atria... : American Journal of
Therapeutics Stroke Risk Scores as Predictors of Severe Outcomes in Atrial Fibrillation: A …

Aims The aim of this study was to observe the percentage of thromboembolic and
haemorrhagic events over a 2-year follow-up in patients with non-valvular atrial fibrillation …

Aims and objectives To gain in‐depth knowledge of patients' experiences of the consultation
processes at a multidisciplinary atrial fibrillation outpatient clinic in a university hospital in …

Background Although the benefits of antithrombotic drugs are indisputable to reduce
thrombotic events, they carry a high risk of compromising patient safety. No previous studies …

Objective: Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are
efficacious in reducing stroke risk among patients with nonvalvular atrial fibrillation (NVAF) …

Background: The aim of this study was to evaluate clinical outcome after left atrial
appendage (LAA) occlusion in real clinical practice and compare between Amplatzer …

Background Anti-thrombotic reduces thromboembolic events but increases bleeding in
patients with atrial fibrillation (AF). We evaluated the benefit–risk of anti-platelet and anti …